| scholarly article | Q13442814 |
| P50 | author | Alexandra Stolzing | Q42314826 |
| Ana Novakovic | Q84393539 | ||
| P2093 | author name string | Matthias Schwab | |
| Richard Schäfer | |||
| Christoph H Gleiter | |||
| William H Frey | |||
| Sandra Beer-Hammer | |||
| Tilo Biedermann | |||
| Georg Siegel | |||
| Barbara Proksch | |||
| Lusine Danielyan | |||
| Marine Buadze | |||
| Ali Lourhmati | |||
| Claire Fabian | |||
| Philipp Kahle | |||
| P2860 | cites work | Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies | Q24554351 |
| Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin | Q24682639 | ||
| Expression of constitutively active erythropoietin receptor in pyramidal neurons of cortex and hippocampus boosts higher cognitive functions in mice | Q30475059 | ||
| Microglia differentiation using a culture system for the expansion of mice non-adherent bone marrow stem cells | Q31053844 | ||
| Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies | Q33726660 | ||
| Advances in progenitor cell therapy using scaffolding constructs for central nervous system injury. | Q33870573 | ||
| Mesenchymal stem cells in a transgenic mouse model of multiple system atrophy: immunomodulation and neuroprotection | Q33916838 | ||
| Intranasal delivery of cells to the brain. | Q34016739 | ||
| Bridging grafts and transient nerve growth factor infusions promote long-term central nervous system neuronal rescue and partial functional recovery | Q34351483 | ||
| Delayed intranasal delivery of hypoxic-preconditioned bone marrow mesenchymal stem cells enhanced cell homing and therapeutic benefits after ischemic stroke in mice | Q34432396 | ||
| Mesenchymal stem cells for the treatment of neurodegenerative disease. | Q34473474 | ||
| Intranasal mesenchymal stem cell treatment for neonatal brain damage: long-term cognitive and sensorimotor improvement | Q34542001 | ||
| Hypoxia promotes dopaminergic differentiation of mesenchymal stem cells and shows benefits for transplantation in a rat model of Parkinson's disease | Q34559310 | ||
| Erythropoietin enhances long-term neuroprotection and neurogenesis in neonatal stroke | Q34673506 | ||
| Nasal administration of opioids for pain management in adults | Q34760508 | ||
| Age-dependent astroglial vulnerability to hypoxia and glutamate: the role for erythropoietin | Q35017110 | ||
| Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model | Q35747138 | ||
| CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery. | Q36112863 | ||
| Neuroprotection in multiple sclerosis | Q36368890 | ||
| Formation and maintenance of Alzheimer's disease beta-amyloid plaques in the absence of microglia | Q36487090 | ||
| Erythropoietin improves neuronal proliferation in dentate gyrus of hippocampal formation in an animal model of Alzheimer's disease | Q36529533 | ||
| Microglial activation and antioxidant responses induced by the Parkinson's disease protein α-synuclein | Q36640417 | ||
| Biodistribution of neural stem cells after intravascular therapy for hypoxic-ischemia | Q36797965 | ||
| Intranasal delivery of neural stem/progenitor cells: a noninvasive passage to target intracerebral glioma | Q36861449 | ||
| Effects of intravenous administration of allogenic bone marrow- and adipose tissue-derived mesenchymal stem cells on functional recovery and brain repair markers in experimental ischemic stroke | Q36997873 | ||
| Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy. | Q37079075 | ||
| Intranasal treatment of central nervous system dysfunction in humans | Q37142166 | ||
| Cellular immune response to intrastriatally implanted allogeneic bone marrow stromal cells in a rat model of Parkinson's disease | Q37236894 | ||
| Intranasal delivery to the central nervous system: mechanisms and experimental considerations | Q37624592 | ||
| Involvement of immune response in the pathogenesis of amyotrophic lateral sclerosis: a therapeutic opportunity? | Q37734499 | ||
| Mesenchymal stem cells: Mechanisms of immunomodulation and homing | Q37762880 | ||
| Intranasal delivery of biologics to the central nervous system | Q37961386 | ||
| Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin | Q38403090 | ||
| Intranasal delivery of mesenchymal stem cells significantly extends survival of irradiated mice with experimental brain tumors | Q38648551 | ||
| Transplantation of a novel human cord blood-derived neural-like stem cell line in a rat model of cortical infarct. | Q40111708 | ||
| Disparate host response and donor survival after the transplantation of mesenchymal or neuroectodermal cells to the intact rodent brain | Q40142380 | ||
| Similar protective effects of BQ-123 and erythropoietin on survival of neural cells and generation of neurons upon hypoxic injury | Q40344679 | ||
| Macrophages and inflammation in the central nervous system | Q40489629 | ||
| The time course of loss of dopaminergic neurons and the gliotic reaction surrounding grafts of embryonic mesencephalon to the striatum | Q41106061 | ||
| Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease | Q41753192 | ||
| Intra-arterial delivery is not superior to intravenous delivery of autologous bone marrow mononuclear cells in acute ischemic stroke. | Q42152041 | ||
| Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice | Q42243192 | ||
| Alzheimer disease macrophages shuttle amyloid-beta from neurons to vessels, contributing to amyloid angiopathy. | Q42380907 | ||
| AAV9-mediated erythropoietin gene delivery into the brain protects nigral dopaminergic neurons in a rat model of Parkinson's disease | Q43281704 | ||
| Leukocyte infiltration and glial reactions in xenografts of mouse brain tissue undergoing rejection in the adult rat brain. A light and electron microscopical immunocytochemical study | Q43641321 | ||
| Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Aβ₂₅₋₃₅ non-transgenic mouse model of Alzheimer's disease | Q44363046 | ||
| Systemically administered human bone marrow-derived mesenchymal stem home into peripheral organs but do not induce neuroprotective effects in the MCAo-mouse model for cerebral ischemia. | Q45364855 | ||
| A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease | Q45883058 | ||
| Survival, neuron-like differentiation and functionality of mesenchymal stem cells in neurotoxic environment: the critical role of erythropoietin. | Q45927294 | ||
| Continuous intraventricular infusion of erythropoietin exerts neuroprotective/rescue effects upon Parkinson's disease model of rats with enhanced neurogenesis | Q46187074 | ||
| The SPECT imaging shows the accumulation of neural progenitor cells into internal organs after systemic administration in middle cerebral artery occlusion rats | Q46524695 | ||
| Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease | Q46942969 | ||
| The blockade of endothelin A receptor protects astrocytes against hypoxic injury: common effects of BQ-123 anderythropoietin on the rejuvenation of the astrocyte population | Q47767135 | ||
| Nasal administration of stem cells: a promising novel route to treat neonatal ischemic brain damage. | Q48122882 | ||
| Brain erythropoietin receptor expression in Alzheimer disease and mild cognitive impairment | Q48176932 | ||
| Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease | Q48247414 | ||
| Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies | Q48401512 | ||
| Marrow stromal cells transplanted to the adult brain are rejected by an inflammatory response and transfer donor labels to host neurons and glia | Q48460765 | ||
| Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. | Q48468481 | ||
| Immune blood biomarkers of Alzheimer disease patients | Q48684327 | ||
| Erythropoietin improves memory function with reducing endothelial dysfunction and amyloid-beta burden in Alzheimer's disease models | Q48833407 | ||
| Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease. | Q50527409 | ||
| LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide. | Q51817662 | ||
| Erythropoietin promotes neuronal replacement through revascularization and neurogenesis after neonatal hypoxia/ischemia in rats. | Q53534081 | ||
| P921 | main subject | Alzheimer's disease | Q11081 |
| microglia | Q1622829 | ||
| mesenchymal stem cell | Q1922379 | ||
| P304 | page(s) | S123-39 | |
| P577 | publication date | 2014-10-09 | |
| P1433 | published in | Cell Transplantation | Q15761863 |
| P1476 | title | Intranasal delivery of bone marrow-derived mesenchymal stem cells, macrophages, and microglia to the brain in mouse models of Alzheimer's and Parkinson's disease | |
| P478 | volume | 23 Suppl 1 |
| Q38679561 | Accelerating stem cell trials for Alzheimer's disease |
| Q39412033 | Anti-Inflammatory Modulation of Microglia via CD163-Targeted Glucocorticoids Protects Dopaminergic Neurons in the 6-OHDA Parkinson's Disease Model. |
| Q45740164 | Cell Therapy for Parkinson's Disease |
| Q52094729 | Cell therapy in the treatment of bipolar mania in an animal model: a proof of concept study. |
| Q104142348 | Challenges and translational considerations of mesenchymal stem/stromal cell therapy for Parkinson's disease |
| Q90148315 | Curcumin-Activated Mesenchymal Stem Cells Derived from Human Umbilical Cord and Their Effects on MPTP-Mouse Model of Parkinson's Disease: A New Biological Therapy for Parkinson's Disease |
| Q52568314 | Current Perspectives regarding Stem Cell-Based Therapy for Alzheimer's Disease. |
| Q33597885 | Effect of intranasal stem cell administration on the nigrostriatal system in a mouse model of Parkinson's disease |
| Q57464992 | Exosomes in perspective: a potential surrogate for stem cell therapy |
| Q48534103 | Fasudil Enhances Therapeutic Efficacy of Neural Stem Cells in the Mouse Model of MPTP-Induced Parkinson's Disease |
| Q47941437 | Functional role of mesenchymal stem cells in the treatment of chronic neurodegenerative diseases. |
| Q90247278 | Homing of Super Paramagnetic Iron Oxide Nanoparticles (SPIONs) Labeled Adipose-Derived Stem Cells by Magnetic Attraction in a Rat Model of Parkinson's Disease |
| Q35548329 | Human mesenchymal stem cells - current trends and future prospective |
| Q42368133 | Human mesenchymal stromal cells as cellular drug-delivery vectors for glioblastoma therapy: a good deal? |
| Q38806320 | Human umbilical cord mesenchymal stem cells delivering sTRAIL home to lung cancer mediated by MCP-1/CCR2 axis and exhibit antitumor effects |
| Q90641955 | Imaging of intranasal drug delivery to the brain |
| Q60952623 | Impact and Challenges of Mesenchymal Stem Cells in Medicine: An Overview of the Current Knowledge |
| Q37689887 | In Vivo Assessment of Stem Cells for Treating Neurodegenerative Disease: Current Approaches and Future Prospects |
| Q92816537 | Intranasal Administration of Mesenchymal Stem Cells Ameliorates the Abnormal Dopamine Transmission System and Inflammatory Reaction in the R6/2 Mouse Model of Huntington Disease |
| Q90216638 | Intranasal Delivery of Bone Marrow Stromal Cells Preconditioned with Fasudil to Treat a Mouse Model of Parkinson's Disease |
| Q48117495 | Intranasal delivery of stem cell-based therapies for the treatment of brain malignancies. |
| Q38342080 | Intranasal delivery of stem cells as therapy for central nervous system disease |
| Q92650424 | Mesenchymal Stromal Cell Therapeutic Delivery: Translational Challenges to Clinical Application |
| Q64767457 | Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases |
| Q50543411 | Mesenchymal stem cells and cell-derived extracellular vesicles protect hippocampal neurons from oxidative stress and synapse damage induced by amyloid-β oligomers. |
| Q30374437 | Mesenchymal stem cells that located in the electromagnetic fields improves rat model of Parkinson's disease |
| Q47228668 | Migratory potential of transplanted glial progenitors as critical factor for successful translation of glia replacement therapy: The gap between mice and men. |
| Q60045149 | Mitochondrial transfer from mesenchymal stem cells to neural stem cells protects against the neurotoxic effects of cisplatin |
| Q47280331 | Modulating Neurotrophin Receptor Signaling as a Therapeutic Strategy for Huntington's Disease |
| Q38843840 | Moving from the Dish to the Clinical Practice: A Decade of Lessons and Perspectives from the Pre-Clinical and Clinical Stem Cell Studies for Alzheimer's Disease |
| Q64980742 | Nasal administration of mesenchymal stem cells restores cisplatin-induced cognitive impairment and brain damage in mice. |
| Q91699174 | Nasal delivery of Fasudil-modified immune cells exhibits therapeutic potential in experimental autoimmune encephalomyelitis |
| Q38999345 | Neurotrophin Signaling and Stem Cells-Implications for Neurodegenerative Diseases and Stem Cell Therapy |
| Q91765663 | Olfactory Ensheathing Cells: A Trojan Horse for Glioma Gene Therapy |
| Q38353261 | Opportunities and challenges: stem cell-based therapy for the treatment of ischemic stroke. |
| Q52603658 | Recent Advances: Decoding Alzheimer's Disease With Stem Cells. |
| Q38749247 | Synergistic and Superimposed Effect of Bone Marrow-Derived Mesenchymal Stem Cells Combined with Fasudil in Experimental Autoimmune Encephalomyelitis |
| Q26800181 | The Dark Side of the Force - Constraints and Complications of Cell Therapies for Stroke |
| Q55610792 | The Route by Which Intranasally Delivered Stem Cells Enter the Central Nervous System. |
| Q36790753 | Treating non-motor symptoms of Parkinson's disease with transplantation of stem cells |
Search more.